Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464880
Status:
COMPLETED
Last Update Posted:
2007-11-29
First Post:
2007-04-21
Brief Title:
Effects of Aliskiren Irbesartan and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-Blind Parallel-Group Cross-Over 4-Period 4 Treatment Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With IncipientOvert Diabetic Nephropathy
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipientovert diabetic nephropathy
Detailed Description:
Antiproteinuric Effects of Aliskiren Renin Inhibitor Irbesartan Angiotensin Receptor Antagonist and the Combination in Hypertensive Patients With Type 2 Diabetes and IncipientOvert Diabetic Nephropathy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None